Eris Lifesciences Q1 FY27: Revenue ₹873 Cr, PAT ₹143 Cr, Up 13% & 14.5% YoY
Eris Lifesciences reported Q1 FY27 consolidated revenue of ₹873 crore, up 13% YoY, and PAT of ₹143 crore, up 14.5% YoY. The DBF segment revenue grew 14.2% to ₹801 crore. The company gained market share in Insulins and leads in GLP-1 prescriptions. International business revenue was ₹72 crore.
The announcement includes detailed financial performance for the quarter, strategic priorities, and updates on key business segments, which are material information for investors.
The company reported strong year-on-year growth in both revenue and profit, with significant market share gains in key therapeutic areas like Insulins and GLP-1, indicating positive business momentum.
Eris Lifesciences Limited announced its financial results for the first quarter of Fiscal Year 2027 (Q1 FY27), reporting a consolidated revenue of ₹873 crore, marking a 13% year-on-year increase. The company's Profit After Tax (PAT) grew by 14.5% year-on-year to ₹143 crore.
The Domestic Branded Formulations (DBF) segment showed robust performance with revenue up 14.2% YoY to ₹801 crore and PAT growth of 14.5% YoY. Seven out of ten therapies in the DBF portfolio achieved double-digit growth. Notably, the Insulin segment saw a significant market share gain, increasing from 9% to 16% since the Biocon acquisition, with Eris's sales growing at 26.4% in a declining market segment. The GLP-1 (Semaglutide) market also saw Eris establish early leadership, securing the top rank in prescriptions and units for its product 'Sundae'.
The International Business segment, Swiss Parenterals, reported revenue of ₹72 crore, a 5% increase YoY, with EBITDA remaining stable. The company is undertaking EU CAPA actions, with sites expected to be audit-ready by December 2026. Long-term strategy for this business remains intact, with Unit-3 commissioning targeted for FY28.
Key priorities for the next two quarters of FY27 include driving growth in the OAD and Cardiac segments, commercializing Eris Bionxt, entering the non-represented Insulin Analogs market, maintaining momentum for 'Sundae', and completing CAPA actions for Swiss Parenterals' sites.
The company also attached an investor presentation detailing these financial highlights and business updates.
What to do with a filing like this
Eris Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Eris Lifesciences Limited. Read the original for the full detail.